## -*-Mode:python-*-   

## LOEs and belief criteria used to predict interactions for the UPIA
## study using the most rigourous criteria on 09/25/2009. in vitro to
## in vivo predictions will be ignored.

## a dictionary holding levels-of-evidence (LOE) for belief criteria for
# each assertion. Each entry has a list of lists holding belief
# criteria for a single assertion in order from the evidence types
# that most support an assertion to those that least. Belief criteria
# are constructed as follows:
#
#    1. a user specifies an integer, Q, specifying the level of
#    evidence required for belief in a single assertion
#
#    2. the elements in each list of levels-of-evidence in the list
#    associated with that assertion are concatenated from 0 to Q-1
#
#
# NOTE: LOEs are simple regular expressions. The DIKB uses pattern
# matching to determine if an assertions evidence meets belief
# criteria. The process is as follows:
#
#        Each regular expression contains patterns for combinations of
#        *ranking categories*. Ranking categories are combinations of
#        evidence types that are believed to have equivalent
#        validity. For example, the ranking category 'non_random',
#        standing for 'non-randomized clinical trial' might consist of
#        evidence types case-control-1 (cc1), case-control-2 (cc2),
#        fixed-order-1 (fo1), and cohort-study-1 (cs1) provided that
#        these evidence types existed in the main evidence type file
#        'evidence_types'. The ranking categories are stored in the file
#        'ranking_categories' in the format:

#        <ranking category>-<evidence type 1>,<evidence type 2>,...,<evidence type n>
#        <ranking category>-<evidence type 1>,<evidence type 2>,...,<evidence type n>
#        ...
       
#        (NOTE: <ranking category> and the comma-seperated list of <evidence type>
#         are seperated by a single '-' and no spaces)

#        So, an example:

#        assume the ranking categories:

#        non_random-cc1,cc2,fo1,cs1
#        iv-iv1,iv2
#        label-lab1
#        rct-rct1
#        ex-ex1
#        cr-cr1,cr2

#        and the rules:

#        (rct){1,}   (one or more randomized controlled trials)
#        (lab){1,1}   (a single drug label evidence type)
#        (iv){1,}.*(non_random){1,}   (one or more in vitro types AND one or more non-randomized trial types)

#        and assume the set of evidence types for the relavant assertion is:
#        ['fo1', 'iv2', 'rct1']

#        Then, the the slot's assessEvidence method would return 'True' because
#        there evidence meets the first and third rules for belief (ony one is necessary)
#
#        NOTE: (TODO) as of 12/11/2007 you cannot specify conjuctive
#        rules for any 'continuous valued' type such as bioavailability,
#        max concentration, or inhibition constant. You can for any
#        non-continous type such as inhibits, substrate_of, etc.

#        NOTE: It is important that you specify conjunctive rules for
#        belief criteria in alphabetical order. For example, the correct
#        way to specify 'one or more in vitro types AND one or more
#        non-randomized trial types' is:
#          (iv){1,}.*(non_random){1,}

#        NOT: (non_random){1,}.*(iv){1,}

#        This is because the rules are applied as a regex search across
#        a string that concatenates, in alphabetical order, all ranking
#        categories from every evidence item that is linked to an
#        assertion. For example, assuming the following evidence items
#        are linked to an assertion:
#           ['rct1', 'iv2',  'fo1', 'rct1']

#        Then, the regex search for a belief criteria rule '(iv){1,}.*(rct){1,}'
#        is applied to the following string:
#            'label iv rct rct'

#        Which will derive the following match objects: ('iv','rct')

#        These correspond to the first set of evidence items that cause
#        an assertion's evidence to meet belief criteria
loe_d = {
    "bioavailability":  [["(pk_ct_pk){1,}","(label_statement){1,}"]],

    "controls_formation_of": [["(pk_ct_pk_genotype){1,}","(pk_ct_pk_phenotype){1,}"],
                              ["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                              ["(iv_met_enz_id_Cyp450_with_inh){1,}"],
                              ["(label_statement){1,}"]],

    "does_not_inhibit": [["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}","(iv_met_inh_microsomal){1,}","(iv_met_inh_recombinant){1,}"],
                         ["(label_statement){1,}"]],

    "first_pass_effect": [["(pk_ct_pk){1,}"],
                          ["(label_statement){1,}"]],

    "fraction_absorbed": [["(pk_ct_pk){1,}"],
                          ["(label_statement){1,}"]],

    "has_metabolite": [["(pk_ct_pk){1,}"],
                       ["(iv_met_enz_id_Cyp450_with_inh){1,}"],
                       ["(label_statement){1,}"]],

    "increases_auc": [["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                      ["(label_statement){1,}"]],
    
    "inhibition_constant": [["(iv_met_inh_microsomal){1,}","(iv_met_inh_recombinant){1,}"],
                            ["(label_statement){1,}"]],
    
    "inhibits": [["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                 ["(iv_met_inh_microsomal){1,}","(iv_met_inh_recombinant){1,}","(label_statement){1,}"]],

    "is_not_substrate_of": [["(pk_ct_pk_phenotype){1,}", "(pk_ct_pk_genotype){1,}"],
                            ["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                            ["(iv_met_enz_id_Cyp450_with_inh){1,}"],
                            ["(label_statement){1,}"]],

    "maximum_concentration": [["(pk_ct_pk){1,}", "(label_statement){1,}"]],

    "primary_metabolic_clearance_enzyme": [["(pk_ct_pk_phenotype){1,}", "(pk_ct_pk_genotype){1,}"],
                                           ["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                                           ["(label_statement){1,}"]],

    "primary_total_clearance_enzyme": [["(pk_ct_pk_phenotype){1,}", "(pk_ct_pk_genotype){1,}"],
                                       ["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                                       ["(label_statement){1,}"]],
    
    "primary_total_clearance_mechanism": [["(pk_ct_pk){1,}"],
                                          ["(label_statement){1,}"]],

    "substrate_of": [["(pk_ct_pk_phenotype){1,}", "(pk_ct_pk_genotype){1,}"],
                     ["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                     ["(iv_met_enz_id_Cyp450_with_inh){1,}"],
                     ["(label_statement){1,}"]],

    ## assertions below this line are 'default assumptions' for the current study. Their
    ## evidence is not evaluated so, these LOEs are not used
    "assumed_effective_dose": [["(label_statement){1,}"]],
        
    "does_not_permanently_deactivate_catalytic_function": [["(iv_met_enz_id_Cyp450_microsomal){1,}", "(iv_met_enz_id_Cyp450_recombinant){1,}"],
                                                           ["(label_statement){1,}"],
                                                           ["(nt_statement){1,}"]],

    'in_vitro_probe_substrate_of_enzyme':[["(iv_met_enz_id_Cyp450_microsomal){1,}", "(iv_met_enz_id_Cyp450_recombinant){1,}"],
                                          ["(label_statement){1,}"],
                                          ["(nt_statement){1,}"]],
    
    "in_vitro_selective_inhibitor_of_enzyme": [["(iv_met_inh_recombinant){1,}"],
                                               ["(iv_met_inh_microsomal){1,}"],
                                               ["(label_statement){1,}"],
                                               ["(nt_statement){1,}"]],
                                               
    'in_viVo_probe_substrate_of_enzyme':  [["(pk_ct_pk_phenotype){1,}", "(pk_ct_pk_genotype){1,}"],
                                            ["(pk_ddi_rndm){1,}","(pk_ddi_non_rndm){1,}"],
                                            ["(label_statement){1,}"],
                                            ["(nt_statement){1,}"]],
                                                
    "in_viVo_selective_inhibitor_of_enzyme": [["(pk_ddi_rndm){1,}"],
                                              ["(pk_ddi_non_rndm){1,}"],
                                              ["(label_statement){1,}"],
                                              ["(nt_statement){1,}"]],
                                              
    "maximum_therapeutic_dose": [["(label_statement){1,}"]],

    "minimum_therapeutic_dose": [["(label_statement){1,}"]],
    
    'pceut_entity_of_concern': [["(pk_ddi_rndm){1,}", "(pk_ddi_non_rndm){1,}", "(obs_eval){1,}", "(label_statement){1,}"],
                                ["(nt_statement){1,}"]],
    
    "permanently_deactivates_catalytic_function": [["(iv_met_enz_id_Cyp450_microsomal){1,}", "(iv_met_enz_id_Cyp450_recombinant){1,}"],
                                                   ["(label_statement){1,}"],
                                                   ["(nt_statement){1,}"]],
    
    "polymorphic_enzyme": [["(pk_ct_pk_phenotype){1,}", "(pk_ct_pk_genotype){1,}"],
                           ["(label_statement){1,}"],
                           ["(nt_statement){1,}"]],
    
    "sole_PK_effect_alter_metabolic_clearance": [["(pk_ddi_rndm){1,}"],
                                                 ["(pk_ddi_non_rndm){1,}"],
                                                 ["(label_statement){1,}"],
                                                 ["(nt_statement){1,}"]],

    }
    

# a dictionary mapping a level-of-evidence that confers a subjective
# level of certainty in each assertion in the DIKB. Each assertion
# receives a number, Q = [1,n], specifying the (index + 1) of an LOE
# in the list of LOEs associated with that assertion in loe_d. For
# assertions where the the kinds of evidence that confer belief for
# the same assertion are thought to be different than the kinds of
# evidence that confer belief against an assertion a tuple is used
# with the following format:
#
#   ((<assertion str>,<level int>), (<assertion str>,<level int>))
#
# Where <assertion str> and <level int> in the first tuple refer
# to the level of evidence heirarchy (from loe_d) and belief criteria
# level (Q) for the evidence_for and <assertion str> and <level int>
# in the second tuple refer to the level of evidence heirarchy
# (from loe_d) and belief criteria level (Q) for the evidence_against.
bc_d = {
    "bioavailability":  1,
    "controls_formation_of": 1,
    "does_not_inhibit": (('does_not_inhibit',1),('inhibits',1)),
    "first_pass_effect": 1,
    "fraction_absorbed": 1,
    "has_metabolite": 1,
    "increases_auc": 1,
    "inhibition_constant": 1,
    "inhibits": (('inhibits',1),('does_not_inhibit',1)),
    "is_not_substrate_of":1,
    "maximum_concentration": 1,
    "primary_metabolic_clearance_enzyme": 1,
    "primary_total_clearance_enzyme": 1,
    "primary_total_clearance_mechanism": 1,
    "substrate_of": 1,

    ## assertions below this line are 'default assumptions' for the current study. Their
    ## evidence is not evaluated so, these belief criteria are not used
    "assumed_effective_dose": 1,
    "does_not_permanently_deactivate_catalytic_function": 1,
    'in_vitro_probe_substrate_of_enzyme': 1,
    "in_vitro_selective_inhibitor_of_enzyme": 1,
    "in_viVo_probe_substrate_of_enzyme": 1,
    "in_viVo_selective_inhibitor_of_enzyme": 1,
    "maximum_therapeutic_dose": 1,
    "minimum_therapeutic_dose": 1,
    'pceut_entity_of_concern': 1,
    "permanently_deactivates_catalytic_function": 1,    
    "polymorphic_enzyme": 1,
    "sole_PK_effect_alter_metabolic_clearance": 1,
    }
